{"organizations": [], "uuid": "9d6e43da9c7937dde0b2fc59756f195a27323834", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20180409&t=2&i=1249495656&w=1200&r=LYNXMPEE3808T", "site_section": "http://feeds.reuters.com/reuters/UKBusinessNews/", "section_title": "Reuters: Business News", "url": "https://uk.reuters.com/article/us-novartis-avexis/novartis-shells-out-8-7-billion-to-buy-avexis-idUKKBN1HG0FT", "country": "US", "domain_rank": 408, "title": "Novartis shells out $8.7 billion to buy AveXis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-09T08:01:00.000+03:00", "replies_count": 0, "uuid": "9d6e43da9c7937dde0b2fc59756f195a27323834"}, "author": "", "url": "https://uk.reuters.com/article/us-novartis-avexis/novartis-shells-out-8-7-billion-to-buy-avexis-idUKKBN1HG0FT", "ord_in_thread": 0, "title": "Novartis shells out $8.7 billion to buy AveXis", "locations": [], "entities": {"persons": [{"name": "reuters/arnd wiegmann  novartis", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "basel", "sentiment": "none"}, {"name": "schweizerhalle", "sentiment": "none"}, {"name": "switzerland", "sentiment": "none"}, {"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "avexis reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9, 2018 / 5:02 AM / Updated 6 minutes ago Novartis shells out $8.7 billion to buy AveXis Reuters Staff 1 Min Read \nZURICH (Reuters) - Novartis ( NOVN.S ) said on Monday it plans to buy AveXis ( AVXS.O ) for $218 per share in a cash deal totaling $8.7 billion as the Swiss drugmaker adds a company whose top drug hopeful, for spinal muscular atrophy, has U.S. breakthrough therapy designation. Logo of Swiss drugmaker Novartis is seen at its branch in Schweizerhalle near Basel, Switzerland, March 29, 2018. REUTERS/Arnd Wiegmann \nNovartis is flush with cash, having just agreed to sell its stake in a consumer healthcare joint venture for $13 billion to GlaxoSmithKline ( GSK.L ). Reporting by", "external_links": [], "published": "2018-04-09T08:01:00.000+03:00", "crawled": "2018-04-09T08:21:40.001+03:00", "highlightTitle": ""}